The short version of Mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-13. Anything still debated is marked as such rather than presented as settled.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
In chemistry, an ester is a compound derived from an acid (either organic or inorganic) in which the hydrogen atom (H) of at least one acidic hydroxyl group (−OH) of that acid is replaced by an organyl group (R′). These compounds contain a distinctive functional group. Analogues derived from oxygen replaced by other chalcogens belong to the ester category as well. According to some authors, organyl derivatives of acidic hydrogen of other acids are esters as well (e.g. amides), but not according to the IUPAC. Glycerides are fatty acid esters of glycerol; they are important in biology, being one of the main classes of lipids and comprising the bulk of animal fats and vegetable oils. Lactones are cyclic carboxylic esters; naturally occurring lactones are mainly 5- and 6-membered ring lactones. Lactones contribute to the aroma of fruits, butter, cheese, vegetables like celery and other foods. Esters can be formed from oxoacids (e.g. esters of acetic acid, carbonic acid, sulfuric acid, phosphoric acid, nitric acid, xanthic acid), but also from acids that do not contain oxygen (e.g. esters of thiocyanic acid and trithiocarbonic acid). An example of an ester formation is the substitution reaction between a carboxylic acid (R−C(=O)−OH) and an alcohol (R'−OH), forming an ester (R−C(=O)−O−R'), where R stands for any group (typically hydrogen or organyl) and R′ stands for organyl group. Organyl esters of carboxylic acids typically have a pleasant smell; those of low molecular weight are commonly used as fragrances and are found in essential oils and pheromones.
These effects appear to be due to their local anesthetic activity and are not reversed by naloxone. Widening of the QRS complex appears to be a result of a quinidine-like effect of propoxyphene, and sodium bicarbonate therapy appears to have a positive direct effect on the QRS dysrhythmia. Seizures may result from either opioid or local anesthetic effects. Pulmonary edema may result from direct pulmonary toxicity, neurogenic/anoxic effects, or cardiovascular depression. Balance disorder is possible, with risk of falls from standing height.
At typical clinical doses used for Parkinson's disease, selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), increasing brain levels of dopamine. At higher doses, it loses its specificity for MAO-B and also inhibits monoamine oxidase A (MAO-A), which increases serotonin and norepinephrine levels in the brain as well. In addition to its MAOI activity, selegiline is a catecholaminergic activity enhancer (CAE) and enhances the impulse-mediated release of norepinephrine and dopamine in the brain. This action may be mediated by TAAR1 agonism. After administration, selegiline partially metabolizes into levomethamphetamine and levoamphetamine, which act as norepinephrine releasing agents (NRAs) and may contribute to its therapeutic and adverse effects as well. The levels of these metabolites are much lower with the ODT and transdermal patch forms of selegiline. Chemically, selegiline is a substituted phenethylamine and amphetamine, a derivative of methamphetamine, and the purified levorotatory enantiomer of deprenyl (the racemic mixture of selegiline and D-deprenyl). Deprenyl was discovered and studied as an antidepressant in the early 1960s by Zoltan Ecseri, József Knoll, and other colleagues at Chinoin Pharmaceutical Company in Hungary. Subsequently, selegiline was purified from deprenyl and was studied and developed itself. Selegiline was first introduced for medical use, to treat Parkinson's disease, in Hungary in 1977. It was subsequently approved in the United Kingdom in 1982 and in the United States in 1989.
Sources: en.wikipedia.org
Trump signs a bill to fund the Department of Homeland Security, the Secret Service, the Coast Guard, FEMA, TSA, and the Cybersecurity and Infrastructure Security Agency, ending a 76-day partial government shutdown. In ice hockey, the Minnesota Wild defeat the Dallas Stars in six games in the 2026 Stanley Cup playoffs following a 5–2 victory to win a playoff series for the first time since 2015, ending an 11-year drought.
The francium atoms leave the gold target as ions, which are neutralized by collision with yttrium and then isolated in a magneto-optical trap (MOT) in a gaseous unconsolidated state. Although the atoms only remain in the trap for about 30 seconds before escaping or undergoing nuclear decay, the process supplies a continual stream of fresh atoms. The result is a steady state containing a fairly constant number of atoms for a much longer time. The original apparatus could trap up to a few thousand atoms, while a later improved design could trap over 300,000 at a time. Sensitive measurements of the light emitted and absorbed by the trapped atoms provided the first experimental results on various transitions between atomic energy levels in francium. Initial measurements show very good agreement between experimental values and calculations based on quantum theory. The research project using this production method relocated to TRIUMF in 2012, where over 106 francium atoms have been held at a time, including large amounts of 209Fr in addition to 207Fr and 221Fr. Other synthesis methods include bombarding radium with neutrons, and bombarding thorium with protons, deuterons, or helium ions. 223Fr can also be isolated from samples of its parent 227Ac, the francium being milked via elution with NH4Cl–CrO3 from an actinium-containing cation exchanger and purified by passing the solution through a silicon dioxide compound loaded with barium sulfate.
=== Effects in nondiabetic chronic kidney disease === In 2021, the US Food and Drug Administration (FDA) and the EMA expanded the indications for dapagliflozin to include the treatment of people who have chronic kidney disease, but do not have diabetes. Clinical trials have shown these effects of such a treatment: The DIAMOND trial (2017–2019) in treatment periods of six weeks showed no improvement of excess proteins in the urine (proteinuria), a significant deterioration of the kidney's filtration rate (reversible within 6 weeks after dapagliflozin discontinuation), and a significant mean loss of body weight of 1.5 kg. The DAPA-CKD trial (2017–2020) showed in a median treatment period of 2.4 years of participants who had already been under ACE inhibitor or angiotensin II receptor blocker therapy that the events of a sustained decline of 50% in the kidney's filtration rate, kidney failure, or death occurred statistically around eight months later in the treatment group than in the placebo group. In the first 12–16 months of treatment, but the kidney filtration rate was worse in the treatment group than in the placebo group, being slightly less negative in the treatment group than in the placebo group only thereafter.
Nicotine dependence pathophysiology in heavy smokers suggests less efficient network architecture in the brain and disruptions in the topological organization of brain networks, with the altered brain network metrics correlated with the duration of cigarette use and the severity of nicotine dependence. Some long-term effects of nicotine may be irreversible because "it is entirely possible that doses of nicotine achieved in the brains of human smokers can damage or kill mHb [medial habenula] neurons that regulate nicotine avoidance behaviors", but more studies are needed to elucidate this underlying mechanism of nicotine-induced degeneration of the mHb-IPn circuit . A 2026 Nature study revealed that nicotine mimics endogenous acetylcholine in the nucleus accumbens, artificially triggering dopamine release to biologically "tag" behaviors as valuable, high-effort achievements regardless of actual difficulty. During active use, this chemical shortcut causes salience dysregulation and "false productivity," as the brain assigns intense reward signals to trivial tasks independent of outcome quality while displacing ambition for a meaningful achievement.
Sources: en.wikipedia.org
The four substrates of this enzyme are 4-hydroxybenzoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are hydroquinone, oxidised NAD+, water, and carbon dioxide. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-hydroxybenzoate,NAD(P)H:oxygen oxidoreductase (1-hydroxylating, decarboxylating). This enzyme is also called 4-hydroxybenzoate 1-monooxygenase. This enzyme participates in benzoic acid degradation.
== History == Before the development of proximity labeling, determination of protein proximity in cells relied on studying protein-protein interactions through methods such as affinity purification-mass spectrometry and proximity ligation assays. DamID is a method developed in 2000 by Steven Henikoff for identifying parts of the genome proximal to a chromatin protein of interest. DamID relies on a DNA methyltransferase fusion to the chromatin protein to nonnaturally methylate DNA, which can then be subsequently sequenced to reveal genome methylation sites near the protein. Researchers were guided by the fusion protein strategy of DamID to create a method for site-specific labeling of protein targets, culminating in the creation of the biotin protein labelling-based BioID in 2012. Alice Ting and the Ting lab at Stanford University have engineered several proteins that demonstrate improvements in biotin-based proximity labeling efficacy and speed.
=== In microalgal biofilms === EPS is found in the matrix of other microbial biofilms such as microalgal biofilms. The formation of biofilm and structure of EPS share a lot of similarities with bacterial ones. The formation of biofilm starts with reversible absorption of floating cells to the surface. Followed by production of EPS, the adsorption will get irreversible. EPS will colonize the cells at the surface with hydrogen bonding. Replication of early colonizers will be facilitated by the presence of organic molecules in the matrix which will provide nutrients to the algal cells. As the colonizers are reproducing, the biofilm grows and becomes a 3-dimensional structure. Microalgal biofilms consist of 90% EPS and 10% algal cells. Algal EPS has similar components to the bacterial one; it is made up of proteins, phospholipids, polysaccharides, nucleic acids, humic substances, uronic acids and some functional groups, such as phosphoric, carboxylic, hydroxyl and amino groups. Algal cells consume EPS as their source of energy and carbon. Furthermore, EPS protects them from dehydration and reinforces the adhesion of the cells to the surface. In algal biofilms, EPS has two sub-categories; soluble EPS (sEPS) and the bounded EPS (bEPS) with former being distributed in the medium and the latter being attached to the algal cells. Bounded EPS can be further subdivided to tightly bounded EPS (TB-EPS) and loosely bounded EPS (LB-EPS). Several factors contribute to the composition of EPS including species, substrate type, nutrient availability, temperature, pH and light intensity.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.